clear evidence of non-proportionality after that (the hazard for non-HIV individuals seems to be zero, whereas that for HIV individuals is positive.
I do not understand what you mean by 'an increased risk of death at day 30 ' (p. 8. ll. 8-9) . Here you are describing Table 3 , which presents the results of the Cox models. The results are adjusted Mortality Rate Ratios which I interpret to be adjusted hazard ratios. In other words, they are measuring the ratio between the hazards of two individuals which differ on the covariate in question, but which have the same values on other covariates. They apply to all durations, not just day 30. Moreover, if you are using a Cox model you need to distinguish between these hazard ratios, and the ratios between 30-day survival probabilities. If the hazard ratio is, for example, 5.57, as it is for HIV infection, then this means that if the survival probability at 30 days, S(30), for the non-infected is X, then S(30) for the infected is equal to X^5.57.
Since you do not have censored data (it is a retrospective survey), both of these problems could be resolved by changing the method of analysis from Cox regression to logistic regression. You could estimate two logistic regression models, one of survival to 30 days (1 = survived, 0 did not), and another of survival to 365 days (1 = survived, 0 did not). If you did this, then the coefficients you estimate would directly be interpretable as 30-day and 365-day survival probabilities, Moreover, the logistic model makes no assumption about the proporationality of the effect of any covariates on the hazard.
2. What do you mean by the sentence ' [o] nly variables that were >90% complete were evaluated (p. 6, ll. 5-6)? Do you mean that you did not consider covariates where more than 10 per cent of cases had missing values? And, if so, do you mean that you excluded them from the analysis completely, or included them in the models as controls but did not evaluate their effect on mortality?
3. On p. 7, l. 1, define 'IDU'.
VERSION 1 -AUTHOR RESPONSE
Reviewer Name PIERLUIGI VIALE There are several concerns about the results of the study. Difference in SAB outcome would be expected to have the main impact in the first 30 days, when the patient has active infection; in the study the survival curves looks superimposable during the first 30 days. So the big differences that occur at the tail of the survival curve could be driven by several confounding variables. Namely it is impossible that all patients with HIV infection was static during the entire study period; some have worsening disease, other have improving disease. Accounting for this may increase the possibility of a relationship between immunological and virological markers and outcome. Secondly, the broad time period of the study is a confounder, because to be infected by HIV during the pre-HAART period was a completely different condition that in the HAART era. Probably including some type of weightening in the regression model would improve the performance of the model. Finally some of the immunological patterns appear to be anlyzed as contiuous variables or mean value. I think that it would be important to look at specific thresholds with respect to risk.
Reply: Thank you for bringing our attention to the importance of the time aspect. We agree that SAB very likely has the greatest impact on mortality within the first 30 days. A proper analysis of long-term outcome should include time-updated variables. Naturally, some of the more important variables in the context of HIV infection such as CD4 cell count and HIV RNA viral load are not available for the non-HIV infected population. For these reasons we have decided to delete all analyses and mention of long-term outcome including figure 1. The broad time period of the study could be a confounder. However, our results were unchanged when we included time period (pre-, early-, and late-ART) in our regression models. We have now clearly stated in the results section that time period was considered in the evaluation of factors associated with outcome and reinfection. The immunological parameters were included as a continuous variable because they provided the best fitting regression model. We did repeat our analyses using CD4 cell count cut-off values of 200 and 350 and did not detect any associations (data not shown). Reviewer Name Andrew Hinde 1. The paper uses a Cox proportional hazards model. This not ideal for the data. No test of the validity of the assumption of proportional hazards is offered. The survival curves in Figure 1 suggest that the assumption may be reasonable for the first 100 days, but there is clear evidence of nonproportionality after that (the hazard for non-HIV individuals seems to be zero, whereas that for HIV individuals is positive.
I do not understand what you mean by 'an increased risk of death at day 30' (p. 8. ll. 8-9). Here you are describing Table 3 , which presents the results of the Cox models. The results are adjusted Mortality Rate Ratios which I interpret to be adjusted hazard ratios. In other words, they are measuring the ratio between the hazards of two individuals which differ on the covariate in question, but which have the same values on other covariates. They apply to all durations, not just day 30. Moreover, if you are using a Cox model you need to distinguish between these hazard ratios, and the ratios between 30-day survival probabilities. If the hazard ratio is, for example, 5.57, as it is for HIV infection, then this means that if the survival probability at 30 days, S(30), for the non-infected is X, then S(30) for the infected is equal to X^5.57.
Since you do not have censored data (it is a retrospective survey), both of these problems could be resolved by changing the method of analysis from Cox regression to logistic regression. You could estimate two logistic regression models, one of survival to 30 days (1 = survived, 0 did not), and another of survival to 365 days (1 = survived, 0 did not). If you did this, then the coefficients you estimate would directly be interpretable as 30-day and 365-day survival probabilities, Moreover, the logistic model makes no assumption about the proporationality of the effect of any covariates on the hazard. Reply: Thank you for your insightful comment. We have followed your suggestion and have changed our regression analysis from a Cox to a logistic regression. The findings remain largely similar although the odds ratios in some instances differ from the hazard ratios. We have decided not to present the 365 day survival analysis, please see our reply to Dr. Viale above.
2. What do you mean by the sentence '[o]nly variables that were >90% complete were evaluated (p. 6, ll. 5-6)? Do you mean that you did not consider covariates where more than 10 per cent of cases had missing values? And, if so, do you mean that you excluded them from the analysis completely, or included them in the models as controls but did not evaluate their effect on mortality? Reply: Covariates with more than 10% missing were excluded. We have clarified this by adding the following to the statistics section: "Variables with more than 10% missing were excluded from analysis." 3. On p. 7, l. 1, define 'IDU'. Reply: IDU is defined in the introduction in line 4. 
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